✦ LIBER ✦

Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease

✍ Scribed by G. Van Assche; F. Baert; S. Vermeire

Book ID: 108606634
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 52 KB
Volume: 35
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2012.05023.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Commentary: BMI and the need for adalimu

Commentary: BMI and the need for adalimumab dose escalation in Crohn's disease – authors’ reply

✍ E. Bultman; C. J. van der Woude 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

Predictors of dose escalation of adalimu

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

✍ E. Bultman; C. de Haar; A. van Liere-Baron; H. Verhoog; R. L. West; E. J. Kuiper 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB

Predictors of adalimumab dose escalation

Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center

✍ Russell D. Cohen; Jeffrey R. Lewis; Hannah Turner; Laura E. Harrell; Stephen B. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require

Infliximab dose escalation vs. initiatio

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis

✍ G. G. KAPLAN; C. HUR; J. KORZENIK; B. E. SANDS 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB

Adalimumab for the treatment of fistulas

Adalimumab for the treatment of fistulas in patients with Crohn's disease

✍ Steven N. Fine 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 2 views

Early clinical remission and normalisati

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

✍ L. S. Kiss; T. Szamosi; T. Molnar; P. Miheller; L. Lakatos; A. Vincze; K. Palatk 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB